Make the handover clear before the responsibility moves.

NHS England's published Shared Care Protocols page says its January 2025 review date has passed and advises local governance review before use (NHS England, 2022). A national template therefore cannot be treated as automatically current for every local arrangement. The proposed brief would record the source, version, review status and local adoption position. Where status is unknown, it would remain an open question. This simple discipline can prevent an apparently thorough analysis from being built on a protocol whose currency has never been established.

What happens when a result is missing, a person cannot be contacted or the usual clinician is absent? Who receives an urgent question and how does an unaccepted request return? These scenarios test whether the arrangement can be used under pressure. A readiness review should also examine whether participating teams have the capacity and information needed for their proposed role. An agreement that assumes unavailable staff time is not made operational by adding another tracker or a more polished set of instructions.

An initial PHARMORIS evaluation could use an approved protocol, related local process documents and synthetic exception cases. Compare preparation of a responsibility brief with the team's current review method. Independent primary-care, specialist and medicines-governance reviewers would define essential questions and unacceptable inferences. The first scope would not accept shared care, transfer prescribing or interpret patient results. It would test whether the support identifies ambiguity accurately and reduces the effort of preparing a discussion that the organisations still need to conduct.

Stop if a draft treats an expired template as current, assigns a responsibility that has not been accepted or implies that one party must take over a task merely because it appears in a document. Reassess if correcting the brief takes longer than the normal review. If organisations disagree about the arrangement, the next step is a governance discussion. A tool can make that disagreement easier to see; it cannot legitimately remove it by choosing the more convenient interpretation.

A specialist medicines lead, primary-care representative and governance owner can start with the current documents and the decision they need to make. We can discuss a bounded preparation study with a credible comparator and explicit stop criteria. The potential value is a more inspectable and efficient review of shared responsibilities. PHARMORIS remains under development, and this page describes a proposed organisational use case. No current clinical deployment, accepted shared-care agreement or achieved improvement in patient outcomes is implied.